Create Free Account

By creating account you will get access to hot stocks & personalised emails

Boston Scientific Corp

Healthcare US BSX

89.11USD
1.08(1.23%)

Last update at 2024-12-19T18:53:00Z

Day Range

87.7289.10
LowHigh

52 Week Range

44.3556.90
LowHigh

Fundamentals

  • Previous Close 88.03
  • Market Cap81892.38M
  • Volume2330820
  • P/E Ratio68.17
  • Dividend Yield1.94%
  • EBITDA3503.00M
  • Revenue TTM13757.00M
  • Revenue Per Share TTM9.52
  • Gross Profit TTM 8679.00M
  • Diluted EPS TTM0.82

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 1141.00M 1076.00M -138.00000M 687.00M 1422.00M
Minority interest - - - - -
Net income 698.00M 1041.00M -140.00000M 4700.00M 1671.00M
Selling general administrative 4520.00M 4359.00M 3787.00M 3941.00M 3569.00M
Selling and marketing expenses - - - - -
Gross profit 8679.00M 8128.00M 6403.00M 7554.00M 6940.00M
Reconciled depreciation 803.00M 741.00M 1123.00M 1011.00M 894.00M
Ebit 1649.00M 2043.00M 1044.00M 1518.00M 1816.00M
Ebitda 2800.00M 2784.00M 1833.00M 2082.00M 2415.00M
Depreciation and amortization 1151.00M 741.00M 789.00M 564.00M 599.00M
Non operating income net other -38.00000M 218.00M 362.00M -358.00000M 156.00M
Operating income 1649.00M 2043.00M 1044.00M 1518.00M 1506.00M
Other operating expenses 10649.00M 10064.00M 9229.00M 8995.00M 8164.00M
Interest expense 470.00M 341.00M 361.00M 473.00M 241.00M
Tax provision 443.00M 36.00M 2.00M -4013.00000M -249.00000M
Interest income 470.00M 341.00M 361.00M 30.00M 3.00M
Net interest income -470.00000M -341.00000M -361.00000M -443.00000M -238.00000M
Extraordinary items - - - 4102.00M 67.00M
Non recurring 376.00M 889.00M 908.00M 323.00M 244.00M
Other items - - - - -
Income tax expense 443.00M 36.00M 2.00M -4013.00000M -249.00000M
Total revenue 12682.00M 11888.00M 9913.00M 10735.00M 9823.00M
Total operating expenses 6646.00M 6304.00M 5719.00M 5814.00M 5281.00M
Cost of revenue 4003.00M 3760.00M 3510.00M 3181.00M 2883.00M
Total other income expense net -508.00000M -967.00000M -1182.00000M -831.00000M 3.00M
Discontinued operations - - - - -
Net income from continuing ops 698.00M 1041.00M -81.00000M 4700.00M 1671.00M
Net income applicable to common shares 642.00M 986.00M -115.00000M 4700.00M 1671.00M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 32470.00M 32230.00M 30778.00M 30565.00M 20998.00M
Intangible assets 5903.00M 6120.00M 5916.00M 7886.00M 6372.00M
Earning assets - - - - -
Other current assets 350.00M 385.00M 410.00M 324.00M 922.00M
Total liab 14896.00M 15607.00M 15451.00M 16688.00M 12273.00M
Total stockholder equity 17574.00M 16623.00M 15327.00M 13877.00M 8725.00M
Deferred long term liab 144.00M 310.00M 330.00M 595.00M 328.00M
Other current liab 2701.00M 3011.00M 3017.00M 2764.00M 2330.00M
Common stock 17.00M 17.00M 17.00M 16.00M 16.00M
Capital stock 17.00M 17.00M 17.00M 16.00M 16.00M
Retained earnings -750.00000M -1392.00000M -2378.00000M -2253.00000M -6953.00000M
Other liab 1831.00M 2140.00M 2239.00M 2954.00M 2210.00M
Good will 12920.00M 11988.00M 9951.00M 10176.00M 7911.00M
Other assets -1.00000M 2.00M 3.00M 4599.00M -2.00000M
Cash 928.00M 1925.00M 1734.00M 217.00M 146.00M
Cash and equivalents 928.00M 1925.00M 1734.00M 217.00M 146.00M
Total current liabilities 3803.00M 4274.00M 3681.00M 4866.00M 5260.00M
Current deferred revenue 220.00M 208.00M 138.00M 144.00M 328.00M
Net debt 8354.00M 7526.00M 7805.00M 10060.00M 6884.00M
Short term debt 20.00M 261.00M 13.00M 1416.00M 2253.00M
Short long term debt 20.00M 261.00M 13.00M 1416.00M 2253.00M
Short long term debt total 9282.00M 9451.00M 9539.00M 10277.00M 7030.00M
Other stockholder equity 18038.00M 17735.00M 17481.00M 15844.00M 15629.00M
Property plant equipment 2832.00M 2252.00M 2084.00M 2079.00M 1782.00M
Total current assets 5760.00M 6317.00M 6694.00M 4699.00M 4003.00M
Long term investments 407.00M 412.00M 918.00M 458.00M 424.00M
Net tangible assets 11670.00M -1723.00000M 9410.00M -4185.00000M -5557.00000M
Short term investments - - - - -
Net receivables 1970.00M 1778.00M 1531.00M 1933.00M 1608.00M
Long term debt 8915.00M 8795.00M 9118.00M 8586.00M 4797.00M
Inventory 1867.00M 1610.00M 1351.00M 1579.00M 1166.00M
Accounts payable 862.00M 794.00M 513.00M 542.00M 349.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 269.00M 263.00M 207.00M 270.00M 33.00M
Additional paid in capital - - - - -
Common stock total equity 17.00M 17.00M 17.00M 16.00M 16.00M
Preferred stock total equity - - - - -
Retained earnings total equity -750.00000M -1392.00000M -2378.00000M -2253.00000M -6953.00000M
Treasury stock -2251.00000M -2251.00000M -2251.00000M -1717.00000M -1717.00000M
Accumulated amortization - - - - -
Non currrent assets other 707.00M 563.00M 545.00M 735.00M 932.00M
Deferred long term asset charges - - - - -
Non current assets total 26710.00M 25911.00M 24081.00M 25866.00M 16997.00M
Capital lease obligations 352.00M 395.00M 408.00M 282.00M 6.00M
Long term debt total 8915.00M 8804.00M 9130.00M 8592.00M 4803.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 56.00M 15.00M -146.00000M -348.00000M -172.00000M
Change to liabilities -255.00000M 408.00M -28.00000M 93.00M -1795.00000M
Total cashflows from investing activities -2011.00000M -1597.00000M -411.00000M -5041.00000M -1921.00000M
Net borrowings -165.00000M -165.00000M -999.00000M 2794.00M 1405.00M
Total cash from financing activities -548.00000M -95.00000M 293.00M 2973.00M 1432.00M
Change to operating activities -209.00000M -134.00000M -316.00000M 27.00M -1336.00000M
Net income 698.00M 1041.00M -82.00000M 4700.00M 1671.00M
Change in cash -1042.00000M 173.00M 1388.00M -222.00000M -188.00000M
Begin period cash flow 2168.00M 1995.00M 607.00M 829.00M 1017.00M
End period cash flow 1126.00M 2168.00M 1995.00M 607.00M 829.00M
Total cash from operating activities 1526.00M 1870.00M 1508.00M 1836.00M 310.00M
Issuance of capital stock 0.00000M 0.00000M 1950.00M 123.00M 101.00M
Depreciation 1136.00M 1093.00M 1123.00M 1011.00M 894.00M
Other cashflows from investing activities -1423.00000M -1057.00000M 111.00M -4233.00000M -1434.00000M
Dividends paid -55.00000M -55.00000M -28.00000M 28.00M 28.00M
Change to inventory -321.00000M -346.00000M -65.00000M -290.00000M -83.00000M
Change to account receivables -220.00000M -279.00000M 335.00M -130.00000M -110.00000M
Sale purchase of stock 136.00M 110.00M -535.00000M 123.00M 101.00M
Other cashflows from financing activities 2806.00M -150.00000M 6724.00M 7410.00M 2502.00M
Change to netincome 410.00M 100.00M 205.00M 312.00M -4.00000M
Capital expenditures 612.00M 554.00M 376.00M 461.00M 316.00M
Change receivables -220.00000M -279.00000M 335.00M -130.00000M -110.00000M
Cash flows other operating 79.00M -146.00000M 21.00M -3858.00000M -262.00000M
Exchange rate changes - - - 10.00M -8.00000M
Cash and cash equivalents changes -1033.00000M 178.00M 1390.00M -222.00000M -187.00000M
Change in working capital -1005.00000M -351.00000M 42.00M -282.00000M -2160.00000M
Stock based compensation 220.00M 194.00M 170.00M 157.00M 140.00M
Other non cash items 540.00M 17.00M 337.00M 551.00M -148.00000M
Free cash flow 914.00M 1316.00M 1132.00M 1375.00M -6.00000M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BSX
Boston Scientific Corp		 1.08 1.23% 89.11 68.17 24.57 5.85 4.26 6.46 26.80
ABT
Abbott Laboratories		 1.29 1.15% 113.22 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 -0.41 0.11% 358.76 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 0.41 0.51% 80.44 26.60 15.87 3.35 2.08 3.90 14.12
SEMHF
Siemens Healthineers AG		 - -% 55.83 39.57 21.32 3.01 3.29 2.95 16.92

Reports Covered

Stock Research & News

View All

Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Corp

300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234

Key Executives

Name Title Year Born
Mr. Michael F. Mahoney Chairman, Pres & CEO 1965
Mr. Daniel J. Brennan Exec. VP & CFO 1966
Mr. Joseph M. Fitzgerald Exec. VP & Group Pres of Cardiology 1964
Mr. Jeffrey B. Mirviss Exec. VP & Pres of Peripheral Interventions 1966
Mr. John Bradley Sorenson Exec. VP of Global Operations 1968
Mr. Jonathan R Monson VP, Global Controller & Chief Accounting Officer NA
Ms. Jodi Euerle Eddy Sr. VP and Chief Information & Digital Officer 1973
Ms. Susan Vissers Lisa VP of Investor Relations 1969
Mr. Vance R. Brown Sr. VP, Gen. Counsel & Corp. Sec. NA
Ms. Catherine Jennings VP of Global Marketing & New Bus. Devel. of Peripheral Interventions NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.